Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal

• Published in: PLoS pathogens 2024-09, Vol.20 (9), p.e1012083
• Main Authors: Cisneros, William J, Soliman, Shimaa H A, Walter, Miriam, Simons, Lacy M, Cornish, Daphne, De Fabritiis, Simone, Halle, Ariel W, Kim, Eun-Young, Wolinsky, Steven M, Lorenzo-Redondo, Ramon, Shilatifard, Ali, Hultquist, Judd F
• Format: Article
• Language: English
• Subjects: Biology and Life Sciences; Health aspects; HIV (Viruses); Medicine and Health Sciences; Physical Sciences; Physiological aspects; Research and Analysis Methods; Transcription factors; Virus latency; Virus research
• ISSN: 1553-7374; 1553-7366; 1553-7374
• DOI: 10.1371/journal.ppat.1012083

The persistence of HIV-1 in long-lived latent reservoirs during suppressive antiretroviral therapy (ART) remains one of the principal barriers to a functional cure. Blocks to transcriptional elongation play a central role in maintaining the latent state, and several latency reversal strategies focus on the release of positive transcription elongation factor b (P-TEFb) from sequestration by negative regulatory complexes, such as the 7SK complex and BRD4. Another major cellular reservoir of P-TEFb is in Super Elongation Complexes (SECs), which play broad regulatory roles in host gene expression. Still, it is unknown if the release of P-TEFb from SECs is a viable latency reversal strategy. Here, we demonstrate that the SEC is not required for HIV-1 replication in primary CD4+ T cells and that a small molecular inhibitor of the P-TEFb/SEC interaction (termed KL-2) increases viral transcription. KL-2 acts synergistically with other latency reversing agents (LRAs) to reactivate viral transcription in several cell line models of latency in a manner that is, at least in part, dependent on the viral Tat protein. Finally, we demonstrate that KL-2 enhances viral reactivation in peripheral blood mononuclear cells (PBMCs) from people living with HIV (PLWH) on suppressive ART, most notably in combination with inhibitor of apoptosis protein antagonists (IAPi). Taken together, these results suggest that the release of P-TEFb from cellular SECs may be a novel route for HIV-1 latency reactivation.